Older Lymphoma Patients Focus of New Study
Dr. Aileen Go of Loyola University Health System, who is studying treatment options for older leukemia and lymphoma patients, has won a prestigious Amgen Foundation Fellowship grant. Go is studying the use of umbilical cord blood transplants grown from cord blood cells outside the body. The transplants are intended for patients ages 55 to 75, who previously have been excluded from such treatments.
Patients will receive high-dose chemotherapy, which, in addition to killing cancer cells also destroys the patient's immune system cells. To build a new immune system, patients receive transplanted stem cells, which develop into new immune system cells.
Older patients generally cannot tolerate high-dose chemotherapy. Go and Stiff will study a reduced-intensity chemotherapy regimen, as well as a method for boosting the number of stem cells.
The stem cells will come from donated umbilical cord blood. A newborn's cord blood does not contain enough stem cells for most adult patients. So the cord blood will be sent to a lab that will grow more stem cells prior to the transplant.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
